Opendata, web and dolomites

TRS SIGNED

A paradigm change in the treatment of blinding ocular diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TRS project word cloud

Explore the words cloud of the TRS project. It provides you a very rough idea of what is the project "TRS" about.

candidate    strategy    causes    relieve    molecule    corticosteroids    hundreds    local    gain    selecting    immune    orphan    risk    clinical    inspired    merely    autoimmune    people    profits    inflammation    platform    2028    reliefs    engineer    indication    uveitic    shares    bio    therapeutic    first    millions    exclusivity    expand    trial    drug    tax    disrupt    treat    company    penetration    capability    us    believe    secure    re    preclinical    blindness    ocular    disease    broad    gt    iia    excellent    lasting    symptoms    700    devastating    shorter    extended    exceed    post    tarsius    steroid    mechanism    safe    patients    correspond    perform    burden    urgent    commercialization    array    saving    2024    inflammatory    market    society    time    diseases    class    steroids    treating    500    financing    global    approved    unmet    effect    launch    economic    medical    requiring    treatment    grant    infectious    revenue    worldwide    glaucoma    billion    itself    impose    pipeline    25    reinvested   

Project "TRS" data sheet

The following table provides information about the project.

Coordinator
TARSIUS PHARMA LTD 

Organization address
address: 19 YAHALOM ST.
city: ZICHRON YAAKOV
postcode: 3093765
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙461˙500 €
 EC max contribution 2˙423˙050 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TARSIUS PHARMA LTD IL (ZICHRON YAAKOV) coordinator 2˙423˙050.00

Map

 Project objective

Ocular inflammatory diseases – affecting hundreds of millions of people worldwide – impose a significant medical and economic burden on society and can lead to blindness. Today, corticosteroids are the most common method used to treat ocular non-infectious inflammation of any kind. Rather than treating the disease itself, however, steroids merely relieve its symptoms, and long-term use can result in devastating consequences. Our bio-inspired drug candidate is a non-steroid. It approaches inflammatory diseases from within the immune system and was developed to ‘re-engineer’ the immune system. Based on excellent preclinical results, we believe that this approach will have the capability to disrupt the immune mechanism that causes the disease in order to provide patients with a safe and long-lasting therapeutic effect, with the goal of saving them from blindness. Our platform technology has the potential to effectively treat a broad array of autoimmune and inflammatory diseases and to become a first in class, market approved molecule for local treatment of inflammatory ocular diseases. Our first target indication is uveitic glaucoma – a devastating orphan disease requiring urgent treatment and carrying high risk of blindness. Selecting an orphan indication as a market penetration strategy will grant us extended market exclusivity, tax reliefs and shorter time to market. In the project, we will perform a Phase I/IIa clinical trial. We will exploit the trial results to secure financing for further clinical development towards commercialization. The global ocular inflammation treatment market is expected to exceed more than US$ 500 Billion by 2024. As our first target indication has a significant unmet need with no approved treatment, we expect to gain 25% of market shares 5 years post launch, which would correspond to >€700 M in revenue for Tarsius in 2028 for uveitic glaucoma only. Profits will be reinvested to develop our product pipeline and expand our company.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More